Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 13/20 | 0.48 |
| ▸ | FABP3 | P05413 | 4/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.44 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108038 | 0.90 | FABP4 (0.47) | FABP4FABP3FABP5GSK3BNPBWR1 | |
| SCHEMBL5101622 | 0.87 | NPBWR1 (0.46) | FABP4FABP3FABP5GSK3BSLC16A3 | |
| SCHEMBL5095060 | 0.86 | GSK3B (0.46) | FABP4FABP3FABP5GSK3BHTR2C | |
| SCHEMBL5102003 | 0.85 | GSK3B (0.46) | FABP4FABP3FABP5GSK3BSLC16A3 | |
| SCHEMBL5107927 | 0.83 | CNR2 (0.49) | FABP4FABP3FABP5MAPT | |
| SCHEMBL5094794 | 0.81 | GSK3B (0.42) | FABP4GSK3BSLC16A3SLC16A1NPBWR1 | |
| SCHEMBL5108059 | 0.80 | NPBWR1 (0.44) | FABP4FABP3FABP5GSK3BSLC16A3 | |
| SCHEMBL5094943 | 0.80 | PLA2G10 (0.42) | FABP4FABP3FABP5MAPT | |
| SCHEMBL5098396 | 0.78 | GSK3B (0.42) | FABP4FABP3FABP5GSK3B | |
| SCHEMBL5094868 | 0.78 | GPR183 (0.42) | FABP4FABP3FABP5GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314877-B2 | Benzofuran derivative | KOWA CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20060189621-A1 | Benzofuran derivative | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1602655-A1 | BENZOFURAN DERIVATIVE | Kowa Co., Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189621-A1 | Benzofuran derivative | TNF, TNFRSF1A, RELA | FABP4 408/4885FABP3 1305/4885FABP5 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.